Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma

Zhen Zhang; Fan-Fan Li; Ming-Dian Lu; Shang-Xin Zhang; Yong-Xiang Li

doi:10.18632/oncotarget.22464

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma

Zhen Zhang, Fan-Fan Li, Ming-Dian Lu, Shang-Xin Zhang and Yong-Xiang Li _

PDF | HTML | How to cite

Oncotarget. 2017; 8:103283-103289. https://doi.org/10.18632/oncotarget.22464

Metrics: PDF 1871 views | HTML 2013 views | ?

Abstract

Zhen Zhang1, Fan-Fan Li2, Ming-Dian Lu1, Shang-Xin Zhang1 and Yong-Xiang Li1

1Department of Gastrointestinal Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, China

2Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence to:

Yong-Xiang Li, email: [email protected]

Keywords: NY-ESO-1; antibody; intrahepatic cholangiocarcinoma; prognosis

Received: May 23, 2017 Accepted: October 28, 2017 Published: November 15, 2017

ABSTRACT

Anti-NY-ESO-1 antibody is observed in a multitude of malignancies. This study was aimed to evaluate the expression of serum anti-NY-ESO-1 antibodies and its prognostic value in intrahepatic cholangiocarcinoma. A total of 103 patients with intrahepatic cholangiocarcinoma were enrolled in the study. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the serum level of anti-NY-ESO-1 antibody. Western blotting was performed to assess the NY-ESO-1 expression in tumor and adjacent tissues. The serum NY-ESO-1 antibody was detected in 18.4% of patients with intrahepatic cholangiocarcinoma, a value that was significantly higher than that in patients with chronic Hepatitis B. Serum NY-ESO-1 antibody was positively correlated with tumor differentiation, lymphatic metastasis, cTNM stage and abdominal pain. Finally, there was a higher cumulative survival rate in patients with serum NY-ESO-1 positivity than in those with serum NY-ESO-1 negativity among the patients with stage III + IV. Our data uncovered that NY-ESO-1 antibody might be a helpful tumor marker and prognostic predictor in intrahepatic cholangiocarcinoma.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22464

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma

Abstract